BlackRock
XFOR icon

BlackRock’s X4 Pharmaceuticals XFOR Stock Holding History

BlackRock’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9M Buy
5,554,906
+4,343,112
+358% +$17.8M ﹤0.01% 3101
2026
Q1 		$5M Sell
1,211,794
-15,014
-1% -$56.2K ﹤0.01% 3829
2025
Q4 		$4.91M Buy
1,226,808
+1,164,874
+1,881% +$4.23M ﹤0.01% 3846
2025
Q3 		$212K Sell
61,934
-117,294
-65% -$302K ﹤0.01% 4672
2025
Q2 		$341K Sell
179,228
-201,782
-53% -$826K ﹤0.01% 4530
2025
Q1 		$2.7M Buy
381,010
+12,322
+3% +$170K ﹤0.01% 3900
2024
Q4 		$8.11M Sell
368,688
-5,001
-1% -$79.7K ﹤0.01% 3530
2024
Q3 		$7.5M Buy
373,689
+17,824
+5% +$372K ﹤0.01% 3550
2024
Q2 		$6.19M Buy
355,865
+64,669
+22% +$2.12M ﹤0.01% 3610
2024
Q1 		$12.1M Buy
291,196
+10,612
+4% +$295K ﹤0.01% 3248
2023
Q4 		$7.06M Buy
280,584
+8,689
+3% +$211K ﹤0.01% 3552
2023
Q3 		$8.89M Sell
271,895
-31,281
-10% -$1.36M ﹤0.01% 3404
2023
Q2 		$17.6M Buy
303,176
+291,723
+2,547% +$15M ﹤0.01% 3116
2023
Q1 		$299K Buy
11,453
+2,297
+25% +$67.3K ﹤0.01% 4673
2022
Q4 		$273K Sell
9,156
-490
-5% -$23.2K ﹤0.01% 4765
2022
Q3 		$494K Buy
9,646
+398
+4% +$13.8K ﹤0.01% 4734
2022
Q2 		$268K Buy
9,248
+188
+2% +$7.15K ﹤0.01% 4957
2022
Q1 		$476K Sell
9,060
-92
-1% -$5.28K ﹤0.01% 4881
2021
Q4 		$628K Buy
9,152
+204
+2% +$25.8K ﹤0.01% 4808
2021
Q3 		$1.42M Buy
8,948
+172
+2% +$28.3K ﹤0.01% 4460
2021
Q2 		$1.71M Sell
8,776
-27,616
-76% -$6.94M ﹤0.01% 4342
2021
Q1 		$9.4M Buy
36,392
+1,942
+6% +$510K ﹤0.01% 3608
2020
Q4 		$6.64M Buy
34,450
+1,577
+5% +$310K ﹤0.01% 3570
2020
Q3 		$6.68M Buy
32,873
+438
+1% +$105K ﹤0.01% 3450
2020
Q2 		$9.07M Buy
32,435
+3,250
+11% +$890K ﹤0.01% 3237
2020
Q1 		$8.76M Buy
29,185
+2,532
+9% +$718K ﹤0.01% 3068
2019
Q4 		$8.55M Buy
26,653
+3,089
+13% +$1.11M ﹤0.01% 3317
2019
Q3 		$8.98M Buy
23,564
+8,347
+55% +$3.3M ﹤0.01% 3261
2019
Q2 		$6.85M Buy
15,217
+13,888
+1,045% +$7.06M ﹤0.01% 3426
2019
Q1 		$694K Sell
1,329
-83
-6% -$45.8K ﹤0.01% 4025
2018
Q4 		$589K Buy
1,412
+153
+12% +$58.4K ﹤0.01% 4042
2018
Q3 		$368K Buy
1,259
+16
+1% +$6.79K ﹤0.01% 4186
2018
Q2 		$812K Buy
1,243
+265
+27% +$868K ﹤0.01% 3968
2018
Q1 		$4.03M Buy
+978
New +$2.85M ﹤0.01% 3483

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock's XFOR Position: Q2 2026 in Review

BlackRock increased its X4 Pharmaceuticals (XFOR) stake by 358% in Q2 2026, buying an estimated $17.8M and bringing the position to 5,554,906 shares worth $25.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3101.

BlackRock first reported a position in XFOR in Q1 2018 and has held it in 34 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • BlackRock held 5,554,906 shares of X4 Pharmaceuticals worth $25.9M as of Q2 2026.
  • BlackRock bought 4,343,112 X4 Pharmaceuticals shares in Q2 2026, an estimated $17.8M.
  • X4 Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3101 holding.
  • BlackRock first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 34 quarters since.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.